Life is busy, work is hard, money is tight and there’s never enough time in the day. That’s the reality for many people, and it’s causing what meQuilibrium calls the epidemic of the 21st century: stress. “What we’re passionate about is what we think is the next piece of healthcare that hasn’t been addressed at […]
Insurers are not the only healthcare companies realizing that they have to care about wellness and revamp their business model to survive. At CONVERGE this week, Alan Ying of Chrysalis Ventures spoke with Craig Lipset of Pfizer about what changes are required for a pharma company to move from selling pills to selling data, and […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The U.S. healthcare system has been “spectacularly incompetent” in creating a sustainable model to benefit American citizens, according to Dr. Alan Ying of Chrysalis Ventures. For healthcare investors that means the future will require a laser-like focus on one area more than any other: cost. The old model of pouring cash into new drugs, new […]
You might think that a market’s growth rate tumbling to about 1 percent from 10 percent a few years ago would worry the companies in that market. But not when that annual market is in the neighborhood of $175 billion annually, according to Scott Seidelmann, CEO of Cleveland-area radiology company Radisphere. “I’m not focused on […]
Telemedicine is a growing field and no moreso than in radiology. The radiology outsourcing market was once was dominated by disparate, local groups, but in recent years national and regional players have begun gobbling up more and more customers. That's made radiology outsourcing companies -- which typically perform radiological services both on-site at hospitals and remotely in what's known as teleradiolgy -- an increasingly attractive target for investors.
Obstetricians, nurse-midwives and labor and delivery nurses now have a powerful — and inexpensive — tool for assessing a woman’s risk of delivering a baby too early. CerviLenz. The disposable device made by CerviLenz Inc. — a Chagrin Falls, Ohio, startup — was introduced today at the American Academy of Obstetricians and Gynecologists annual meeting […]
Sixteen-year-old Chrysalis Ventures saw the recent worldwide financial crisis as an opportunity to invest in Middle America. While some venture firms spent the crisis hoarding their cash, or investing more in existing portfolio companies, the Louisville, Ky., firm made seven new investments in the Midwest and South last year. That included a $4 million co-investment […]
Louisville-based Chrysalis Ventures led the round, accompanied by Health Evolution Partners and Foundation's management team. The company plans to use the funding to further invest in its technology and "expand its geographic footprint."
The company is developing a disposable device that measures the length of a woman's cervix to help predict risks of preterm birth. It is potentially easier, less costly and just as accurate as the transvaginal ultrasound device used in only high-risk pregnancies. It could be in the market by 2010.
The Pittsburgh-based imaging services company will use the $10 million to hire new radiologists and expand its diagnostic imaging and radiology service office. Chrysalis Ventures led the round, accompanied by Health Evolution Partners and another group through its Health Evolution Partners Innovation Network.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
